120 related articles for article (PubMed ID: 38311316)
1.
Lee HG; Lim GH; An JH; Park SM; Seo KW; Youn HY
J Vet Sci; 2024 Jan; 25(1):e1. PubMed ID: 38311316
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
3. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830
[TBL] [Abstract][Full Text] [Related]
4. Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Takahashi H; Ojima H; Shimizu H; Furuse J; Furukawa H; Shibata T
Jpn J Clin Oncol; 2014 Jun; 44(6):570-8. PubMed ID: 24755544
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effect of superoxide dismutase on canine mammary gland tumour in vitro.
Ko BG; An JH; Lee JH; Kim KB; Kim TH; Park SM; Chae HK; Youn HY
Vet Med Sci; 2024 Jan; 10(1):e1323. PubMed ID: 37997503
[TBL] [Abstract][Full Text] [Related]
6. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.
He Q; Gao J; Ge S; Wang T; Li Y; Peng Z; Li Y; Shen L
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1575-83. PubMed ID: 24804814
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models.
Li Q; Kim YS; An JH; Kwon JA; Han SH; Song WJ; Youn HY
BMC Vet Res; 2021 Oct; 17(1):338. PubMed ID: 34702279
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
9. The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts.
Rössler J; Monnet Y; Farace F; Opolon P; Daudigeos-Dubus E; Bourredjem A; Vassal G; Geoerger B
Int J Cancer; 2011 Jun; 128(11):2748-58. PubMed ID: 20715103
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity of Rivoceranib Against Canine Mammary Gland Tumor Cell Lines.
Lee JH; Li Q; An JH; Chae HK; Choi JW; Kim BJ; Song WJ; Youn HY
Anticancer Res; 2019 Oct; 39(10):5483-5494. PubMed ID: 31570442
[TBL] [Abstract][Full Text] [Related]
11. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer.
O'Sullivan C; Edgerly M; Velarde M; Wilkerson J; Venkatesan AM; Pittaluga S; Yang SX; Nguyen D; Balasubramaniam S; Fojo T
J Clin Endocrinol Metab; 2014 Apr; 99(4):1291-7. PubMed ID: 24423320
[TBL] [Abstract][Full Text] [Related]
12. Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors.
Kernt M; Thiele S; Liegl RG; Kernt B; Eibl K; Haritoglou C; Ulbig MW; Kampik A
Growth Factors; 2012 Feb; 30(1):49-61. PubMed ID: 22168366
[TBL] [Abstract][Full Text] [Related]
13. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models.
Giddabasappa A; Lalwani K; Norberg R; Gukasyan HJ; Paterson D; Schachar RA; Rittenhouse K; Klamerus K; Mosyak L; Eswaraka J
Exp Eye Res; 2016 Apr; 145():373-379. PubMed ID: 26927930
[TBL] [Abstract][Full Text] [Related]
14. Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
Canu B; Fioravanti A; Orlandi P; Di Desidero T; Alì G; Fontanini G; Di Paolo A; Del Tacca M; Danesi R; Bocci G
Neoplasia; 2011 Mar; 13(3):217-29. PubMed ID: 21390185
[TBL] [Abstract][Full Text] [Related]
15. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
16. Combined VEGF/PDGF inhibition using axitinib induces αSMA expression and a pro-fibrotic phenotype in human pericytes.
Siedlecki J; Asani B; Wertheimer C; Hillenmayer A; Ohlmann A; Priglinger C; Priglinger S; Wolf A; Eibl-Lindner K
Graefes Arch Clin Exp Ophthalmol; 2018 Jun; 256(6):1141-1149. PubMed ID: 29721663
[TBL] [Abstract][Full Text] [Related]
17. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
[TBL] [Abstract][Full Text] [Related]
18. In vitro evaluation of Axitinib and Sorafenib treatment in glioblastoma cell viability and morphology.
Opriţa A; Dobrescu MA; Manea EV; Popescu ŞO; Sevastre AS; Pîrvu AS; Buzatu IM; Tache DE
Rom J Morphol Embryol; 2023; 64(2):173-180. PubMed ID: 37518874
[TBL] [Abstract][Full Text] [Related]
19. Macrophage induces anti-cancer drug resistance in canine mammary gland tumor spheroid.
Lim GH; An JH; Park SM; Youn GH; Oh YI; Seo KW; Youn HY
Sci Rep; 2023 Jun; 13(1):10394. PubMed ID: 37369757
[TBL] [Abstract][Full Text] [Related]
20. Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
Kelly RJ; Rixe O
Target Oncol; 2009 Dec; 4(4):297-305. PubMed ID: 19876699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]